2021
Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging
Young BD, Moreland H, Oatmen KE, Freeburg LA, Shahab Z, Herzog E, Miller EJ, Spinale FG. Cytokine Signaling and Matrix Remodeling Pathways Associated with Cardiac Sarcoidosis Disease Activity Defined Using FDG PET Imaging. International Heart Journal 2021, 62: 21-164. PMID: 34544982, DOI: 10.1536/ihj.21-164.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersCase-Control StudiesCytokinesEvaluation Studies as TopicFemaleFluorodeoxyglucose F18Heart DiseasesHumansImmunosuppressive AgentsInflammationMaleMatrix Metalloproteinase InhibitorsMatrix MetalloproteinasesMiddle AgedPositron-Emission TomographyProspective StudiesRadiopharmaceuticalsReceptors, Interleukin-2Receptors, Tumor Necrosis FactorRisk AssessmentSarcoidosisSeverity of Illness IndexTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AConceptsTumor necrosis factorSoluble cytokine receptorsCardiac sarcoidosisCS patientsMatrix metalloproteinasePlasma MMP-9 levelsFluorodeoxyglucose positron emission tomographyPlasma tumor necrosis factorAnti-inflammatory regimensBiopsy-confirmed sarcoidosisReferent control valuesSarcoidosis disease activityVascular endothelial growth factor receptorHeart failure therapySoluble TNF receptorsEndothelial growth factor receptorMMP-9 levelsSpecific inflammatory pathwaysFDG-PET imagingEndogenous MMP inhibitorsCytokine receptorsPositron emission tomographyCytokine receptor profilesGrowth factor receptorSIL-2R
2017
Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique
Gallegos C, Miller EJ. Use of fluorine-18 sodium fluoride for the diagnosis of transthyretin cardiac amyloidosis: The birth of a new technique. Journal Of Nuclear Cardiology 2017, 25: 1568-1570. PMID: 28357811, DOI: 10.1007/s12350-017-0847-6.Peer-Reviewed Original Research
2016
Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis
Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging 2016, 18: 1057-1064. PMID: 27965280, DOI: 10.1093/ehjci/jew298.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBortezomibBostonCardiomyopathiesCohort StudiesEchocardiography, Doppler, ColorFemaleFollow-Up StudiesHeart Function TestsHospitals, UniversityHumansImmunoglobulin Light-chain AmyloidosisKaplan-Meier EstimateMaleMelphalanMiddle AgedPrognosisRetrospective StudiesROC CurveSensitivity and SpecificitySurvival AnalysisTreatment OutcomeVentricular Dysfunction, LeftConceptsB-type natriuretic peptideFree light chainsLight-chain cardiac amyloidosisCardiac amyloidosisCardiac biomarkersCR groupGlobal LSHigh-dose melphalanLongitudinal systolic strainSerum free light chainsCardiac functional impairmentCardiac functional improvementStandard echocardiographic measuresCardiac function improvementShort-term improvementBNP reductionComplete responseDiastolic functionEchocardiographic measuresHematologic responseNatriuretic peptideSystolic strainFunctional improvementFunction improvementFunctional impairment